Mark L. Baum J.D.
Net Worth

Last updated:

What is Mark L. Baum J.D. net worth?

The estimated net worth of Mr. Mark L. Baum J.D. is at least $91,696,345 as of 22 Mar 2024. He owns shares worth $80,798,445 as insider and has received compensation worth at least $10,897,900 in Harrow Health, Inc..

What is the salary of Mark L. Baum J.D.?

Mr. Mark L. Baum J.D. salary is $838,300 per year as Chief Executive Officer & Chairman in Harrow Health, Inc..

How old is Mark L. Baum J.D.?

Mr. Mark L. Baum J.D. is 52 years old, born in 1973.

What stocks does Mark L. Baum J.D. currently own?

As insider, Mr. Mark L. Baum J.D. owns shares in one company:

Company Title Shares Price per share Total value
Harrow Health, Inc. (HROW) Chief Executive Officer & Chairman 2,137,525 $37.8 $80,798,445

What does Harrow Health, Inc. do?

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

HROW logo
HROW
Harrow Health, Inc.
$37.8

Mark L. Baum J.D. insider trading

Harrow Health, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common stock 9,000 $11.59 $104,310
Option
RSU 150,000 N/A N/A
Option
Common stock 59,836 $10.67 $638,450
Option
Common stock 150,000 $10.67 $1,600,500
Option
Stock Option (Right to Buy) 15,400 $7.71 $118,734
Option
Common stock 15,400 $7.71 $118,734
Purchase
Common Stock 15,000 $8.11 $121,650
Purchase
Common Stock 5,800 $17.05 $98,890
Option
Performance Stock Unit 762,300 N/A N/A
Option
Common Stock 762,300 N/A N/A
Option
Common Stock 180,000 $8.99 $1,618,200
Option
Stock Option (Right to Buy) 180,000 $8.99 $1,618,200
Option
Common Stock 88,000 N/A N/A
Option
Restricted Stock Unit 88,000 N/A N/A
Purchase
Common Stock 25,000 $13.39 $334,750
Option
Stock Option (Right to buy) 125,000 $2.4 $300,000
Option
Common Stock 125,000 $2.4 $300,000
Option
Restricked Stock Unit 850,000 N/A N/A
Option
Common Stock 850,000 N/A N/A
Option
Common Stock 200,000 N/A N/A
Option
Restricted Stock Unit 200,000 N/A N/A
Purchase
Purchase Warrant 156,000 $1.79 $279,240
Purchase
Common Stock 156,000 $1.79 $279,240
Option
Common Stock 200,000 $1.72 $344,000
Option
Restricted Stock Unit 200,000 $1.72 $344,000
Purchase
Warrants 48,262 N/A N/A
Purchase
Convertible Debenture 856,087 $0.67 $571,010

Harrow Health key executives

Harrow Health, Inc. executives and other stock owners filed with the SEC: